Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Odronextamab per linfomi a grandi cellule B recidivanti e refrattari prima del CAR-T

17 novembre 2026 aggiornato da: University of Washington

Odronextamab per i linfomi a grandi cellule B recidivanti/refrattari prima delle terapie definitive mirate ai linfomi

This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Descrizione dettagliata

OUTLINE:

Patients receive odronextamab intravenously (IV) on days 1, 2, 8, 9, 15 and 16 of cycle 1 (dose step-up), and on days 1, 8 and 15 of cycles 2-4 and then once every other week of remaining cycles. Cycles repeat every 21 days for the first 4 cycles, then every other week for up to a total of 12 months (including the first 2 cycles). After 2 cycles, patients undergo leukapheresis followed by lymphodepletion and CAR-T infusion per standard of care. If there is a significant delay of leukapheresis, patients may receive up to 12 additional weeks of treatment. Patients who achieve CR after cycle 2 may opt out of leukapheresis and CAR-T cell infusion and may continue to receive odronextamab in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET)/computed tomography (CT), collection of blood and oral or rectal swab samples and tissue biopsy throughout the study. Additionally, patients may undergo lumbar puncture and bone marrow aspiration and/or biopsy on study.

After completion of study treatment, patients are followed till 90 days or the initiation of the next lymphoma directed therapy for toxicity check, and total duration of follow-up is up to 5 years.

Tipo di studio

Interventistico

Iscrizione (Stimato)

27

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Washington
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • Fred Hutch/University of Washington Cancer Consortium
        • Investigatore principale:
          • Mengyang Di, MD, PhD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histologically confirmed large B cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from indolent lymphoma, follicular lymphoma (FL) grade 3B
  • Measurable disease, defined as at least one measurable lesion ≥ 15 mm on PET, CT, or magnetic resonance imaging (MRI) within one month of screening, according to the International Working Group consensus response evaluation criteria in lymphoma
  • Prior frontline therapy for large B cell lymphoma must have failed the patient, and criteria must be met for receiving commercial axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel) per Food and Drug Administration (FDA) label
  • Age ≥ 18 years
  • Capable of understanding and providing a written informed consent
  • Prior treatment with an anti-CD20 antibody therapy
  • Eastern Cooperative Oncology Group performance status of 0-1; we allow enrollment of patients with a performance status of 2 if it is attributed to lymphoma per discretion of the treating physician or principal investigator (PI)
  • Creatinine clearance ≥ 45 mL/min calculated by Cockcroft-Gault equation
  • Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome
  • Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x the ULN
  • Adequate pulmonary function, defined as ≤ grade 1 dyspnea and oxygen saturation (SpO2) ≥ 92% on room air
  • Adequate cardiac function, defined as left ventricular ejection fraction ≥ 50% and without evidence for pericardial effusion
  • Platelet count ≥ 75 x 10^9 /L
  • Hemoglobin (Hg) level ≥ 9 g/dL
  • Absolute neutrophil count (ANC) ≥ 1 x 10^9 /L
  • Patients with bone marrow involvement or splenic sequestration: Platelet count ≥ 25 x 10^9 /L
  • Patients with bone marrow involvement or splenic sequestration: Hg ≥ 7.0 g/dL
  • Patients with bone marrow involvement or splenic sequestration: ANC ≥ 0.5 x 10^9 /L
  • Negative serum pregnancy test within 2 days of initiating odronextamab for women of childbearing potential (WOCBP), defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
  • Fertile male and WOCBP patients must be willing to use highly effective contraceptive methods from study recruitment to at least 6 months after the CAR T-cell infusion
  • Patients must not provide egg or sperm donation until at least 6 months after the completion of the last dose of Odron

Exclusion Criteria:

  • Detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of cerebrospinal fluid malignant cells or brain metastases. Patients with a history of secondary central nervous system (CNS) lymphoma may be eligible provided that there has been no evidence of CNS disease from lymphoma for at least 3 months at the time of screening
  • History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
  • Standard anti-neoplastic chemotherapy (non-biologic) within 5-times the half-life or within 2 weeks, whichever is shorter, prior to first administration of study drug
  • Standard radiotherapy within 2 weeks of first administration of study drug
  • Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy, unless all the following are met: disease responded to prior bispecific therapy (CR or PR per Lugano criteria) and did not experience disease progression within 12 months of the last dose of prior bispecific therapy, and the tumor must still express CD20 (CD20 examination per standard of care [SOC])
  • Allogeneic stem cell transplantation
  • Any CAR-T cell therapy
  • Patients may not be receiving other investigational agents
  • Treatment with rituximab, alemtuzumab, or other investigational or commercial biologic agent within 2 weeks prior to first administration of study drug
  • Immunosuppressive therapy (other than biologic) within 2 weeks of first administration of study drug
  • Treatment with an investigational non-biologic agent within 2 weeks of first administration of study drug
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition of study drug
  • History of hypersensitivity to any compound in the tetracycline antibiotics group
  • Concurrent active malignancy for which the patient is receiving systemic treatment, unless approved by PI
  • Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection
  • Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) and/or significant pulmonary disease (e.g., obstructive pulmonary disease and history of symptomatic bronchospasm)
  • Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg/day of prednisone or equivalent. A short course of corticosteroid for lymphoma disease control during screening is allowed
  • Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 400) or chronic infection with hepatitis B virus or hepatitis C virus. Patients with hepatitis B (hepatitis B surface antigen positive [HepBsAg+]) with controlled infection were permitted upon consultation with the physician managing the infection
  • Known hypersensitivity to both allopurinol and rasburicase
  • Pregnant or breast-feeding women
  • Administration of live vaccination within 28 days of first administration of study drug

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (odronextamab)

Patients receive odronextamab IV based on the following schedules:

  • Step-up dosing during cycle 1: 0.2 mg on C1D1, 0.5 mg on C1D2, 2 mg on C1D8 and C1D9, respectively, and 10 mg on C1D15 and C1D16, respectively (0.7/4/20 regimen).
  • Dosing during cycles 2-4: Odron will be given at 160 mg weekly.
  • Once every other week at 320 mg of remaining cycles.

Please see the Detailed Description for additional information.

Undergo bone marrow biopsy

Altri nomi:
  • Biopsia del midollo osseo
  • Biopsia, midollo osseo

Ancillary studies

Undergo bone marrow aspiration

Undergo lumbar puncture

Altri nomi:
  • LP
  • Colpetto spinale

Undergo PET/CT

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • Imaging spettroscopico di risonanza magnetica protonica
  • P.T
  • Tomografia a emissione di positroni (procedura)

Undergo PET/CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).

Undergo tissue biopsy

Altri nomi:
  • Bx

Undergo leukapheresis

Altri nomi:
  • Leucocitoferesi
  • Leucoferesi terapeutica
  • Aferesi di adsorbimento dei leucociti
  • Aferesi per la riduzione dei globuli bianchi

Given IV

Altri nomi:
  • REGN1979
  • Anticorpo monoclonale bispecifico anti-CD20 x anti-CD3 REGN1979
  • OMS 11035

Undergo collection of blood and oral or rectal swab samples

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni

Undergo CAR-T cell therapy

Altri nomi:
  • CAR T Infusione
  • Terapia CAR T
  • Terapia CAR-T
  • Infusione di cellule T del recettore dell'antigene chimerico

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Failure to undergo leukapheresis
Lasso di tempo: Up to 5 years

Will include failures due to disease progression or adverse events (AEs) due to odronextamab (Odron), or requirement of other lymphoma-directed therapy for bridging before leukapheresis due to lack of response. Will report the total number and percentage with 95% confidence interval (CI).

Up to 5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Receipt of chimeric antigen receptor T-cell therapy (CAR-T)
Lasso di tempo: Up to 5 years

Will estimate the total number and percentage with 95% CI of patients who receive CAR-T cell infusion. Patients who achieve complete response (CR) after 2 cycles of Odron and opt out of leukapheresis will be excluded from the estimation of the percentage. Will also report the reasons why patients do not eventually receive CAR-T.

Up to 5 years
Overall response rate (ORR) following bridging prior to CAR-T infusion
Lasso di tempo: Up to 5 years

ORR includes CR, partial response, stable disease. Will report the total number and percentage with 95% CI of patients who achieve response on positron emission tomography/computed tomography (PET/CT) scans before CAR-T cell infusion. Patients who receive CAR-T cell infusion will be included in the estimation of this percentage.

Up to 5 years
Progression free survival (PFS) following CAR-T infusion
Lasso di tempo: Up to 2 years

Will estimate the median with interquartile range of the progression free duration. Will also report the percentage with 95% CI.

Up to 2 years
CR rate
Lasso di tempo: At 1 month after CAR-T

Will report the total number and percentage with 95% CI of patients who achieve CR on the PET/CT scans following CAR-T cell infusion.

At 1 month after CAR-T
PFS in patients who achieve CR after 2 cycles of Odron, choose to opt out of CAR-T, and receive up to a total of 12 months of Odron
Lasso di tempo: Up to 5 years

Will report the median duration of PFS with 95% CI in this group of patients.

Up to 5 years
Incidence of AEs
Lasso di tempo: Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first

All AEs will be graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Cytokine release syndrome and immune effector cell associated neurotoxicity syndrome will be graded by the American Society for Transplantation and Cellular Therapy Consensus Grading systems. Will report the rate and grade of each AE, including unsuccessful CAR-T production.

Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 settembre 2025

Completamento primario (Stimato)

10 aprile 2028

Completamento dello studio (Stimato)

11 aprile 2033

Date di iscrizione allo studio

Primo inviato

14 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

14 gennaio 2025

Primo Inserito (Effettivo)

20 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • RG1124641
  • NCI-2024-10534 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • FHIRB0020747 (Altro identificatore: Fred Hutch/University of Washington Cancer Consortium)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .